21 September 2015 - Shire today announced that the European Commission granted Marketing Authorisation for once-daily, non-stimulant Intuniv (guanfacine hydrochloride prolonged release tablets) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.

“The approval of Intuniv marks a significant advance in the treatment of ADHD in children and adolescents in Europe. Previously, physicians had only one licensed non-stimulant option for these patients,” said Perry Sternberg, Senior Vice President, Neuroscience Business Unit, Shire. “The importance of simply providing physicians with the ability to choose the non-stimulant option that may best suit the needs of their patients should not be overlooked, considering the complexities and different manifestations of the disorder in children and adolescents.”

The European Commission decision to grant approval is based on data from three pivotal Phase 3 studies investigating the short- and long-term safety and efficacy of Intuniv in children and adolescents with ADHD.

The European Commission decision to grant Marketing Authorisation follows a positive opinion adopted by the Committee for Medicinal Products for Human Use (CHMP) in July 2015 and applies to all 28 EU member states and Iceland, Liechtenstein and Norway.

For more details, go to: https://www.shire.com/newsroom/2015/september/non-stimulant-for-adhd-approved-in-europe